- Home
- BCML vs FHTX Comparison
BCML vs FHTX Comparison
Compare BCML & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCML | FHTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.6M | 323.4M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCML | FHTX |
|---|---|---|
| Price | $32.06 | $4.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $34.00 | $11.50 |
| AVG Volume (30 Days) | 77.6K | ★ 139.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | 3.81 | ★ 25.32 |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $13.71 | $8.89 |
| Revenue Next Year | $5.25 | $20.13 |
| P/E Ratio | $43.12 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $26.31 | $3.27 |
| 52 Week High | $33.15 | $6.95 |
Technical Indicators
Market Signals| Indicator | BCML | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 50.19 |
| Support Level | $27.59 | $3.59 |
| Resistance Level | $32.86 | $4.64 |
| Average True Range (ATR) | 0.74 | 0.19 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 58.47 | 68.97 |
Price Performance
Historical ComparisonAbout BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses, and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services. The Company operates as one reportable segment: banking operations.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.